Is Bevacizumab Better Than Photodynamic Therapy for Myopic Subretinal Neovascularization?
September 21, 2009
Submit Comments
Yet another nail in the coffin for laser for macular disease. A study in AJO this month demonstrated superior results for Bevacizumab compared to photodynamic therapy (PDT) for myopic subretinal neovascularization (SRN). It would seem a few years from now, we will look at laser treatment for the macula like we look at blood-letting. Oh well- it’s great progress!
Comments
Jump down to form below to submit your own comments
